Cancer cell chemokines direct chemotaxis of activated stellate cells in pancreatic ductal adenocarcinoma

Laboratory Investigation

Volumn 97, Issue 3, 2017, Pages 302-317

  Roy, Ishan ^a   Boyle, Kathleen A ^a   Vonderhaar, Emily P ^a   Zimmerman, Noah P ^a   Gorse, Egal ^a   MacKinnon, A Craig ^a   Hwang, Rosa F ^b   Franco Barraza, Janusz ^c   Cukierman, Edna ^c   Tsai, Susan ^a   Evans, Douglas B ^a   Dwinell, Michael B ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CCL28 CHEMOKINE; CHEMOKINE; CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CXCR6; CXCL16 CHEMOKINE; UNCLASSIFIED DRUG; CHEMOKINE RECEPTOR;

ANIMAL CELL; ARTICLE; CANCER CELL; CHEMOTAXIS; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; EPITHELIUM TUMOR; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMORTALIZED CELL LINE; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREATIC STELLATE CELL; PANCREATITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CELL CULTURE; CELL LINE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE; CELL LINE, TUMOR; CELLS, CULTURED; CHEMOKINES; CHEMOTAXIS; COCULTURE TECHNIQUES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL CELLS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; PANCREATIC NEOPLASMS; PANCREATIC STELLATE CELLS; RECEPTORS, CHEMOKINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 85014533549     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2016.146     Document Type: Article

References (47)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2012;62:10-29.
2. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369: 1691-1703.
3. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364: 1817-1825.
4. El-Hadaad HA, Wahba HA. Oxaliplatin plus 5-fluorouracil and folinic acid (OFF) in gemcitabine-pretreated advanced pancreatic cancer: a phase II study. J Gastrointest Cancer 2013;44:313-317.
5. Postlewait LM, Ethun CG, Kooby DA, et al. Combination gemcitabine/ cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: results of a phase II prospective trial. J Surg Oncol 2016;114:336-341.
6. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15: 2403-2413.
7. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457-1461.
8. Provenzano P, Cuevas C, Chang A, et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012;21:418-429.
9. Rhim A, Oberstein P, Thomas D, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 2014;25:735-747.
10. Özdemir B, Pentcheva-Hoang T, Carstens J, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppres-sion and accelerates pancreas cancer with reduced survival. Cancer Cell 2014;25:719-734.
11. Kim EJ, Sahai V, Abel EV, et al. Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin Cancer Res 2014;20:5937-5945.
12. Goldman J, Eckhardt SG, Borad MJ, et al. Phase I dose-escalation trial of the oral investigational hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors. Clin Cancer Res 2015;21: 1002-1009.
13. Sato N, Maehara N, Goggins M. Gene expression profiling of tumor- stromal interactions between pancreatic cancer cells and stromal fibroblasts. Cancer Res 2004;64:6950-6956.
14. Hwang RF, Moore T, Arumugam T, et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 2008;68: 918-926.
15. Masamune A, Kikuta K, Watanabe T, et al. Hypoxia stimulates pancreatic stellate cells to induce fibrosis and angiogenesis in pancreatic cancer. Am J Physiol Gastrointest Liver Physiol 2008;295:G709-G717.
16. Masamune A, Kikuta K, Watanabe T, et al. Fibrinogen induces cytokine and collagen production in pancreatic stellate cells. Gut 2009;58: 550-559.
17. Apte MV, Haber PS, Applegate TL, et al. Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture. Gut 1998;43: 128-133.
18. Nielsen MFB, Mortensen MB, Detlefsen S. Key players in pancreatic cancer-stroma interaction: cancer-associated fibroblasts, endothelial and inflammatory cells. World J Gastroenterol 2016;22:2678-2700.
19. Bailey JM, Swanson BJ, Hamada T, et al. Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin Cancer Res 2008;14:5995-6004.
20. Gao Z, Wang X, Wu K, et al. Pancreatic stellate cells increase the invasion of human pancreatic cancer cells through the stromal cell-derived factor-1/CXCR4 axis. Pancreatology 2010;10:186-193.
21. Apte M, Pirola R, Wilson J. Pancreatic stellate cells : a starring role in normal and diseased pancreas. Front Physiol 2012;3:344.
22. Tape CJ, Ling S, Dimitriadi M, et al. Oncogenic KRAS regulates tumor cell signaling via stromal reciprocation. Cell 2016;165:910-920.
23. Wendt MK, Johanesen PA, Kang-Decker N, et al. Silencing of epithelial CXCL12 expression by DNA hypermethylation promotes colonic carcinoma metastasis. Oncogene 2006;25:4986-4997.
24. Wendt MK, Cooper AN, Dwinell MB. Epigenetic silencing of CXCL12 increases the metastatic potential of mammary carcinoma cells. Oncogene 2008;27:1461-1471.
25. Ramos EA, Camargo AA, Braun K, et al. Simultaneous CXCL12 and ESR1 CpG island hypermethylation correlates with poor prognosis in sporadic breast cancer. BMC Cancer 2010;10:23.
26. Baumhoer D, Smida J, Zillmer S, et al. Strong expression of CXCL12 is associated with a favorable outcome in osteosarcoma. Mod Pathol 2012;25:522-528.
27. Roy I, Zimmerman NP, Mackinnon AC, et al. CXCL12 chemokine expression suppresses human pancreatic cancer growth and metastasis. PLoS One 2014;9:e90400.
28. Kim MP, Evans DB, Wang H, et al. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc 2009;4:1670-1680.
29. Roy I, McAllister DM, Gorse E, et al. Pancreatic cancer cell migration and metastasis is regulated by chemokine-biased agonism and bioener-getic signaling. Cancer Res 2015;75:3529-3542.
30. Lee HO, Mullins SR, Franco-Barraza J, et al. FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. BMC Cancer 2011;11:245 2407-11-245.
31. Franco-Barraza J, Beacham DA, Amatangelo MD, et al. Preparation of extracellular matrices produced by cultured and primary fibroblasts. Curr Protoc Cell Biol 2016;71:10.9.1-10.9.34.
32. Amatangelo MD, Bassi DE, Klein-Szanto AJ, et al. Stroma-derived three-dimensional matrices are necessary and sufficient to promote desmoplastic differentiation of normal fibroblasts. Am J Pathol 2005;167:475-488.
33. Goetz JG, Minguet S, Navarro-Lerida I, et al. Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell 2011;146:148-163.
34. Rezakhaniha R, Agianniotis A, Schrauwen JT, et al. Experimental investigation of collagen waviness and orientation in the arterial adventitia using confocal laser scanning microscopy. Biomech Model Mechanobiol 2012;11:461-473.
35. Billadeau DD, Chatterjee S, Bramati P, et al. Characterization of the CXCR4 signaling in pancreatic cancer cells. Int J Gastrointest Cancer 2006;37:110-119.
36. Ijichi H, Chytil A, Gorska AE, et al. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J Clin Invest 2011;121:4106-4117.
37. Murakami T, Cardones AR, Finkelstein SE, et al. Immune evasion by murine melanoma mediated through CC chemokine receptor-10. J Exp Med 2003;198:1337-1347.
38. Wente MN, Gaida MM, Mayer C, et al. Expression and potential function of the CXC chemokine CXCL16 in pancreatic ductal adenocarcinoma. Int J Oncol 2008;33:297-308.
39. Guerra C, Schuhmacher AJ, Cañamero M, et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-ras oncogenes in adult mice. Cancer Cell 2007;11:291-302.
40. Walter K, Omura N, Hong S, et al. Pancreatic cancer associated fibro-blasts display normal allelotypes. Cancer Biol Ther 2008;7:882-888.
41. Ogawa H, Iimura M, Eckmann L, et al. Regulated production of the chemokine CCL28 in human colon epithelium. Am J Physiol Gastrointest Liver Physiol 2004;287:G1062-G1069.
42. Facciabene A, Peng X, Hagemann IS, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and treg cells. Nature 2011;475: 226-230.
43. Bayne L, Beatty G, Jhala N, et al. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 2012;21: 822-835.
44. Wang W, Soto H, Oldham ER, et al. Identification of a novel chemo-kine (CCL28), which binds CCR10 (GPR2). J Biol Chem 2000;275: 22313-22323.
45. Goicoechea SM, Bednarski B, Stack C, et al. Isoform-specific upregula-tion of palladin in human and murine pancreas tumors. PLoS One 2010;5:e10347.
46. Mul FPJ, Zuurbier AEM, Janssen H, et al. Sequential migration of neutrophils across monolayers of endothelial and epithelial cells. J Leukoc Biol 2000;68:529-537.
47. Roy I, Evans DB, Dwinell MB. Chemokines and chemokine receptors: update on utility and challenges for the clinician. Surgery 2014;155: 961-973.